ACC/AHA Guidelines for Cardiovascular Disease Prevention and Cholesterol Management:Implications of New Therapeutic Agents^a-中国期刊网

摘要 In2014theAmericanCollegeofCardiology/AmericanHeartAssociationissuedfournewguidelinesforcardiovasculardiseasepreventionthatfocusedoncardiovascularriskassessment,lifestylemanagement,obesitymanagement,andbloodcholesterolmanagement.Thedevelopmentofanatheroscleroticcardiovasculardiseaseriskcalculatorformedthebasisoftheriskassessmentguideline,andthelifestylemanagementguidelinefocusedonrecommendinganevidence-baseddietarypattern.Thebloodcholesterolmanagementguidelinespecificallyidentifiedfourgroupsofpatientsshowntobenefitfrommoderate-intensityorhigh-intensitystatintherapyfrompreviousclinicaltrialsandabandonedtheuseofspecificlow-densitylipoprotein(LDL)cholesterol(LDL-C)goallevelsonthebasisofthelackofclinicaltrialevidence.Therecommendationsfortreatmentwithmoderate-intensityorhigh-intensitystatintherapyarebasedonrigorousevidencefromrandomizedclinicaltrials.Guidancehassincebeenprovidedfortheuseofnonstatintherapies,includingcholesterolabsorptioninhibitorandproproteinconvertasesubtilisin/kexintype9monoclonalantibodytherapywhenadequatereductionofLDL-Clevelsisnotachievedwithmaximallytoleratedstatintherapy.TherecentdevelopmentandapplicationofthesetherapieshaveresultedinremarkablereductionsinLDL-Clevelsthatarewelltolerated,andpreliminaryoutcomedataarepromisinginshowingsubstantialatheroscleroticcardiovasculardiseaseeventreductionsbeyondstatintherapy.

1Sidney C.Smith. The 2013 ACC/AHA Guidelines on Treatment of Blood Cholesterol to Improve Cardiovascular Outcomes:Implications for Statin Use and Dose vs.Target^a.心血管疾病,2016-02.
2Dayi Hu. Dyslipidemia and Management of Atherosclerotic Cardiovascular Diseases in China:New Evidence and New Guidelines.心血管疾病,2017-01.
3Danny J.Eapen;William M.Schultz;Robert E.Heinl;Nima Ghasemzadeh;Tina Varghese;Diana E.Kurian;Christina E.Mathai;Pratik Sandesara;Bryan R.Kindya;Marc P.Allard-Ratick;Neal K.Bhatia;Ijeoma Isiadinso;Laurence Sperling. Primary Prevention of Cardiovascular Disease.心血管疾病,2016-02.
4Li Sheng-De,Zhang Shu-Yang,Peng Bin. Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).医药卫生,2021-03.
5Pan Li,Xiao-Rong Dong,Bei Zhang,Xin-Tong Zhang,Jing-Zhuo Liu,De-Sheng Ma,Li Ma. Molecular mechanism and therapeutic targeting of necrosis, apoptosis, pyroptosis, and autophagy in cardiovascular disease.医药卫生,2021-12.
6Li Xiao-Ying,Shi Zhong-Wei,Zhao Dong,Yin Da-Wei,On behalf of the writing group of 2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease. 2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease.医药卫生,2020-08.
7Nikolai Khaltaev,Svetlana Axelrod. Countrywide cardiovascular disease prevention and control in 49 countries with different socio-economic status.医药卫生,2022-12.
8Wang Yao,Zhang Jie-Fang,Chen Song-Zan,Lyu Qing-Bo,Lyu Xue,Zhang Wen-Bin. ACC/AHA risk score for predicting the presence and severity of coronary artery disease in a Chinese population: a cross-sectional Study.医药卫生,2020-11.
9Chen Cao,Dong Xiaoping. Therapeutic implications of prion diseases.医药卫生,2021-06.
10Christopher Estel;C.Richard Conti. Global Burden of Cardiovascular Disease.心血管疾病,2016-09.

ACC/AHA Guidelines for Cardiovascular Disease Prevention and Cholesterol Management:Implications of New Therapeutic Agents^a

来源期刊

相关推荐

同分类资源更多

相关关键词

ACC/AHA Guidelines for Cardiovascular Disease Prevention and Cholesterol Management:Implications of New Therapeutic Agents^a

来源期刊

相关推荐

同分类资源 更多

相关关键词

同分类资源更多